MONTCLAIR, NJ--(Marketwire - Sep 19, 2012) - MetaStat, Inc. (OTCBB: MTST), a life science company focused on the development and commercialization of proprietary clinical diagnostic and prognostic tests that predict the probability of systemic hematogenous (blood borne) cancer metastasis, as well as companion therapeutics to prevent this deadly spread, today announced positive results from a large patient validation study of its MenaCalc Breast™ cancer metastasis test. The study, performed in collaboration with leading cancer researchers at Yale University, demonstrated that MenaCalc Breast™ has been retrospectively validated as a predictor of survival for patients with breast cancer.
The data was published in an article, "Quantitative assessment of invasive mena isoforms (MenaCalc) as an independent prognostic marker in breast cancer," online on September 12th in Breast Cancer Research, an international, peer-reviewed online journal publishing original research, reviews, commentaries and reports. A link to a copy of the published Breast Cancer Research article is below:
"This is a validation of our earlier research on this new technology platform," Warren C. Lau, President and CEO of MetaStat, Inc. noted. "We are now another step closer to meeting a critical unmet medical need for the 230,000 American and nearly 1.4 million world-wide breast cancer patients and the physicians who treat them."
About MetaStat, Inc.
MetaStat was formed to allow cancer patients to benefit from the latest discoveries in how cancer spreads to other organs in the body. Our mission is to become an industry leader in the emerging field of personalized cancer therapy. We intend to help clinicians better "customize" cancer treatment decisions, by positively identifying high-risk patients who need aggressive therapy and by sparing those at low-risk from the harmful side effects and expense of chemotherapy and/or radiation.
The vast majority of fatalities in solid tumor cancers occur when cancer cells leave the tumor and travel through the bloodstream to other organs in the body in a process called metastasis. The discovery of the mechanism of metastasis was finally made possible because of our use of new tools for the observation and isolation of deadly metastatic cancer cells. We believe our diagnostic product line, including the MetaSite Breast™, MenaCalc Breast™, MenaCalc Lung™ and MenaCalc Prostate™ tests, will accurately predict the probability that cancer will systemically metastasize. These tests could be a breakthrough for cancer patients and their doctors because metastasis is responsible for approximately 90% of fatalities from solid epithelial cancers. Further, we believe our platform technology may be applicable in up to 80% of all solid tumor cancers, including prostate, lung, colorectal, head and neck, and pancreatic. Most significantly, we believe our MenaBloc™ technology provides us with targets of intervention in key pathways for the development of therapeutics that may preemptively reduce or eliminate metastasis.
Our technology platform and corresponding products result from over 15 years of collaboration involving four scientific institutions. We believe we are unique and differentiated in the marketplace because our discoveries are based on direct microscopic visualization of living, functioning tumors in vivo and the behavior of these highly metastatic cells as they migrate to and penetrate blood vessels, where they are subsequently carried away to establish distant site tumors.